The estimated Net Worth of Capital Llc Dst is at least $15 Milion dollars as of 6 April 2023. Capital Dst owns over 62,500 units of Biostage stock worth over $15,015,075 and over the last 7 years Capital sold BSTG stock worth over $13,996.
Sign up
Capital Dst BSTG stock SEC Form 4 insiders trading
Capital has made over 10 trades of the Biostage stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital bought 62,500 units of BSTG stock worth $375,000 on 6 April 2023.
The largest trade Capital's ever made was buying 500,000 units of Biostage stock on 1 September 2021 worth over $1,000,000. On average, Capital trades about 41,845 units every 106 days since 2018. As of 6 April 2023 Capital still owns at least 3,725,825 units of Biostage stock.
You can see the complete history of Capital Dst stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Capital Dst's mailing address?
Capital's mailing address filed with the SEC is C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746.
Insiders trading at Biostage
Over the last 9 years, insiders at Biostage have traded over $962,849 worth of Biostage stock and bought 1,593,581 units worth $3,804,230 . The most active insiders traders include David Green, Capital Llc Dst oraz Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of $217,604. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth $375,000.
What does Biostage do?
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
What does Biostage's logo look like?
Complete history of Capital Dst stock trades at Biostage
Biostage executives and stock owners
Biostage executives and other stock owners filed with the SEC include:
-
David Green,
Director -
Dr. William L. Fodor Ph.D.,
Chief Scientific Officer -
Yu Hong,
Pres -
Thomas Robinson,
Independent Director -
James Shmerling,
Director -
Ting Li,
Director -
Harout DerSimonian,
Chief Scientific Officer -
James Mastridge,
Interim Vice President - Finance, Principal Financial Officer and Principal Accounting Officer -
Hong Yu,
President -
Jason Jing Chen,
Chairman of the Board -
Dr. Shunfu Hu Ph.D.,
VP of Bus. Devel. & Operations -
Peter A. Pellegrino Jr.,
Interim VP of Fin. -
David Green,
CEO & Chairman -
Blaine H. Mc Kee,
Director -
Saverio La Francesca,
See Remarks -
John J Canepa,
Director -
Thomas Mc Naughton,
Chief Financial Officer -
John F Kennedy,
Director -
James Joseph Mc Gorry,
Chief Executive Officer -
William Fodor,
Chief Scientific Officer -
Herman Sanchez,
Director -
Xiaoyu Du,
10% owner -
Matthew D Dallas,
Director -
Wei Zhang,
Director -
Jeffrey E Young,
Director -
Peter M Chakoutis,
Vice President of Finance -
Ronald J Packard,
Director -
Capital Llc Dst,
10% owner -
Jing Chen,
-
Junli He,
CEO -
Joseph Luis Jr Damasio,
Chief Financial Officer